Research & Development

• Multiple Sclerosis
  • PI-2301 Peptide Copolymer
• Crohn’s Disease
  • PI-2301 Peptide Copolymer
• Rheumatoid Arthritis
  • PI-2301 Peptide Copolymer
  • Small Molecule Cathespin S Inhibitors
• Uveitis
  • PI-2301 for Autoimmune Uveitis
• Platform Technology
  • Antibodies
  • Novel Therapeutics
  • Vaccines
• Clinical Trials
• Publications

Clinical Trials

PI-2301 is currently in phase Ib development

Peptimmune has initiated a twelve-week phase Ib MS patient study.

PI-2301 is currently in phase Ib development and is a second-generation copolymer for multiple sclerosis (MS), Crohn’s disease, uveitis, and potentially neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). A Phase Ia safety and pharmacokinetic study has been completed, and all doses of PI-2301 have been found to be safe and well tolerated, along with evidence of bioactivity. Peptimmune has initiated a twelve-week phase Ib MS patient study Q2/2008. This study will confirm repeat-dose safety and proof of pharmacologic mechanism for PI-2301. Phase Ib development is being conducted at multiple sites in France.

read our patient info in French read our patient info in English

Please select from the medical condition or product candidate below:

• Multiple Sclerosis
• PI-2301 for Multiple Sclerosis